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Type 1 diabetes mellitus (T1DM) is an autoimmune disease, where destruction of beta-cells causes insulin deficiency.The incidence
of T1DMhas increased in the last decades and cannot entirely be explained by genetic predisposition. Several environmental factors
are suggested to promote T1DM, like early childhood enteroviral infections and nutritional factors, but the evidence is inconclusive.
Prenatal and early life exposure to environmental pollutants like phthalates, bisphenol A, perfluorinated compounds, PCBs, dioxins,
toxicants, and air pollutants can have negative effects on the developing immune system, resulting in asthma-like symptoms and
increased susceptibility to childhood infections. In this review the associations between environmental chemical exposure and
T1DM development is summarized. Although information on environmental chemicals as possible triggers for T1DM is sparse, we
conclude that it is plausible that environmental chemicals can contribute to T1DM development via impaired pancreatic beta-cell
and immune-cell functions and immunomodulation. Several environmental factors and chemicals could act together to trigger
T1DM development in genetically susceptible individuals, possibly via hormonal or epigenetic alterations. Further observational
T1DM cohort studies and animal exposure experiments are encouraged.
1. Introduction
Type 1 diabetes mellitus (T1DM) is an autoimmune disease
with beta-cell destruction, resulting in insulin deficiency. A
genetic predisposition seems to be necessary for developing
the disease and is most often linked to genes in the HLA-
complex [1]. About 90% of children with T1DM have the
DR4-DQ8 haplotype and/or DR3-DQ2, and those who have
both in combinations have the highest risk for T1DM. Islet
autoantibodies are detected in ∼90% of individuals at the
time of diagnosis of T1DM, and these are directed against
pancreatic proteins like insulin, glutamic acid decarboxylase
(GAD), islet antigen 2 (IA-2), or zinc transporter 8 [2]. These
autoantibodies generally appear in the circulation months to
years before clinical onset.
It has become clear that environmental factors likely play
a role in disease development, due to the facts that there
has been an increasing incidence of type 1 diabetes in the
last decades in many industrial countries and that there is
less than 60% concordance of T1DM among monozygotic
twins [3]. Factors like maternal age at delivery, infections in
early life, deficiency of specific nutrients during pregnancy,
and/or early childhood have been associated with risk of type
1 diabetes in observational studies [4, 5]. Other suggested
environmental risk factors for T1DM are alterations in gut
microbiota [6] and lack of general exposure to microbial
factors (the “hygiene hypothesis”) [7].
This review will focus on the possible impact of envi-
ronmental chemicals on T1DM development. The observed
associations are summarized in Table 1 and the suggested
mechanisms are summarized in Figure 1. Where little or no
data of direct relevance for T1DM are available, we briefly
discuss relevant data on other immune mediated diseases or
on T2DM.
We start with a brief overview of relevant study designs
and models, before we discuss relevant studies with the
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PPARsPPARs
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HormonesMucosal
permeability
Chemicals
Epigenetic
alterations
Microbiota
GLUT2 ERs
X
Y
X
Y
- Cell death (apoptosis, necrosis) 
- Oxidative stress (inflammation, apoptosis) 
- Immunosuppression (impaired phagocytosis, increased infections)
- Immunomodulation (impaired Tregs, Th1/Th2 skewing, and autoimmunity) 
- Molecular mimicry (autoimmunity)
- Posttranslational modifications (beta-cell fucntion, apoptosis) 
- Beta-cell function (impaired insulin response, beta-cell mass)
Figure 1: Mechanisms suggested to be involved in pathways of T1DM development after exposure to environmental chemicals via food/gut,
air/lungs, and skin. Chemicals can act directly on beta or immune cells, by binding to receptors (X and Y-receptors could, for instance, be
adrenergic-, purinergic-, or scavenger receptors) or after uptake in the cells by pinocytosis, endocytosis, or diffusion. Chemicals can also affect
factors like mucosal permeability, the microbiome, or the hormone balance, all shown to interact with the immune system. Several chemicals
have been shown to induce epigenetic changes. Chemical exposures can further lead to apoptosis or cell death, increased oxidative stress,
impaired insulin response, altered immune function or immunosuppression, molecular mimicry, and posttranslational modifications.
specific environmental chemicals, followed by a review of
some potential mechanisms involved.
2. Study Designs Used in T1DM Research
The possible impact of environmental risk factors on T1DM
development has been analysed in epidemiological studies
by comparing the serum or urine levels of the chemi-
cal or their metabolites/biomarkers in T1DM patients and
healthy controls. Interpretation of such studiesmust take into
account the possibility that exposure may have occurred at
or after diagnosis, by considering kinetics of the biomarkers
and the ability of biomarkers to reflect actual exposure.
Potential risk factors that could induce islet autoimmunity
(presence of islet autoantibodies) or the progression from
autoimmunity to development of disease can be investigated
in longitudinal epidemiological studies with serial serum
samples available from early childhood (from before the
presence of autoantibodies and after seroconversion) up to
diagnosis of T1DM. To our knowledge, chemicals have been
determined in few prospective studies of type 1 diabetes
in humans. Epidemiological studies have been limited by
the low incidence of T1DM and the difficulty in accurately
assessing exposures in epidemiological studies of large size.
Some epidemiological studies use proxies for environ-
mental chemical exposures (for instance by self-report in
questionnaires) or use ecological study designs where expo-
sure is not determined at the individual level but only by
region or country, and thesemust be interpretedwith caution.
Animal models allow for controlled exposures of the
chemical in question and are important for establishing
causal relationships and the mechanistic mode of action.The
most commonly used models for T1DM development are
the nonobese diabetic (NOD) mouse and the Bio Breed-
ing (BB) rat demonstrating spontaneous insulitis, influx of
autoimmune cells into pancreatic islets attacking insulin pro-
ducing beta-cells, and T1DM development [8–10]. Another
frequently used model to induce diabetes in mice is by
multiple low dose administrations of the beta-cell specific
toxin streptozotocin, where the beta-cells are destroyed and
the animals rapidly develop diabetes [11]. Increased levels
of serum glucose and insulitis in pancreatic sections are
examples of T1DM features in both animal models, whereas
hyperinsulinemia and insulin resistance in other animal
strains generally are signs of type 2 diabetes (T2DM) develop-
ment. Other models of T1DM, including knock-out variants
of the ones mentioned above, are reviewed elsewhere [12].
In vitro models are suitable to investigate direct effects
on specific cell types, including receptor interactions. The
6 BioMed Research International
most commonly used in vitro beta-cell systems for diabetes
research are the rat beta-cell lines (INS-1E, RIN-m5F) [13, 14],
the mouse beta-cell line (MIN6) [15] and primary islets and
single beta-cells isolated from human, mouse, and rat pan-
creas. Decreased glucose secretion and increased apoptotic
signaling are examples of T1DM-relatedmechanisms in beta-
cells.
3. Environmental Chemicals
This review focuses on environmental chemicals that (i) have
been found to contaminate food, water, and air and (ii)
have been reported to influence the function of beta-cells
or the immune system. These components include persistent
organic pollutants (POPs like PCBs, dioxins, pesticides,
and flame retardants), endocrine disruptors (bisphenol A,
phthalates, and triclosan), certain metals (arsenic, organic
derivatives of tin), N-nitroso compounds, bacterial toxins,
ambient air pollution (such as ozone, particulate matter,
and polycyclic aromatic hydrocarbons), and tobacco smoke.
Some of these are persistent organic pollutants, which are
resistant to environmental degradation and therefore accu-
mulate in nature and the food chain. Other chemicals, includ-
ing many of the endocrine disruptors (such as bisphenol A
and phthalates) have a short half-life in the environment and
have low bioaccumulation in humans.
3.1. Polychlorinated Biphenyls (PCBs). There are 209 con-
figurations of organochlorides with 1 to 10 chlorine atoms,
classified as persistent organic pollutants. PCBs have been
used as dielectric and coolant fluids in electrical equipment
and can be found in marine food and wild animals due to
accumulation in fatty tissue in the food chain.
In a prospective study on pregnant women with diabetes
(primarily type 1), PCB serum levels were associated with
the disease [16]. Another epidemiological study, however,
showed tendency of an inverse association between maternal
serum levels of PCB-135 or p,p󸀠-DDE during pregnancy and
T1DM development in the child, but this was not statistically
significant [17]. In support of PCB effects on autoimmunity,
employees working at a PCB production factory had higher
prevalence of antiglutamic acid decarboxylase (anti-GAD)
autoantibodies in their serum compared to controls [18].
Animal studies reveal induced insulin resistance, indicat-
ing T2DM development, after exposure to a mixture of per-
sistent organic pollutants that mimics the relative abundance
of organic pollutants present in crude salmon oil [19, 20],
and there are several studies indicating associations between
serum PCB levels and T2DM in humans [21, 22]. Dioxins and
dioxin like PCBs act via the aryl hydrocarbon receptor (AhR)
and can cause oxidative stress, apoptosis, and increased
inflammation during metabolization/detoxification of the
chemical [23].
3.2. 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD). TCDD is
primarily formed as a byproduct in the manufacturing of
materials requiring the use of chlorinated phenols and during
the combustion of chlorinated chemical products. TCDD is a
persistent organic pollutant that has been used in herbicides
like Agent Orange [24]. Humans are mostly exposed through
intake of marine food and game due to accumulation of the
chemical in fatty tissue in the food chain.
There are no epidemiological studies investigating associ-
ations between TCDD exposure and T1DM.However, TCDD
has been shown to be highly toxic for INS-1E rat pancreatic
beta-cells regarding survival and ultrastructure via activation
of the aryl hydrocarbon receptor (AhR) [25]. Further, experi-
mental studies have shown that TCDD exposure in C57BL/6J
mice impaired glucose-stimulated secretion of insulin from
the islets via the AhR signaling pathway [26]. TCDD has
also been shown to induce calcium influx via T-type chan-
nels, regulating vesicular trafficking, such as lysosomal and
secretory granule exocytosis, indicating that TCDD might
exert adverse effects on beta-cells by stimulating continuous
insulin release resulting in beta-cell exhaustion in an INS-1
rat beta-cell line [27].
On the other hand, in the NODmousemodel, TCDD has
been shown to prevent T1DM development when adminis-
tered from 8 weeks of age, a time point after the spontaneous
insulitis development is normally initiated (starting from 4
weeks of age in theNODmice [28]), due to increased number
of regulatory T-cells in the pancreas and reduced insulitis
[29]. The immunosuppressive effect of TCDD has been
shown to be due to activation of the aryl hydrocarbon recep-
tor (AhR), which is a ligand-activated transcription factor
in CD4+ Th17 T-cells, and upregulation of IL-22 expression
[30]. IL-22 is secreted by Th17 cells and is highly present in
various autoimmune diseases, but whether IL-22 ismediating
the inflammation itself, or is a byproduct of the inflammation
is depending on the tissue and overall cytokine setting [31].
In agreement with this, in another murine model for autoim-
munity, systemic lupus erythematosus (SLE), TCDD appears
to promote differentiation of regulatory T-cells via AhR and
inhibiting Th17 cells and cause immunosuppressive effects
[32, 33]. Both models indicate a therapeutic effect of AhR
activation in autoimmunity development in adult animals. In
line with the immunosuppressive effects of TCDD via Tregs
stimulation following AhR ligation/activation, TCDD has
also demonstrated suppressive (preventive) effects in rodent
allergy models [34, 35]. Interestingly, other AhR ligands did
not have this suppressive effect on the allergy development,
suggesting that the effect via AhR is ligand specific [34].
On the other hand, TCDD administered during gestation
induced adult autoimmunity in different mice strains [36–
38], suggesting that exposure to chemicals during critical
developmental stages in utero may possibly promote the
development of autoimmune diseases, including T1DM, later
in life.
Human serum levels of TCDD have been associated with
increased insulin plasma levels andT2DM, although there are
some conflicting results from epidemiological studies [39–
42].
3.3. Dichlorodiphenyltrichloroethane (DDT) and Dichlorod-
iphenyldichloroethylene (DDE). The organochloride DDT
and its metabolite DDE have been used as insecticides
triggering spasms via the opening of neuronal ion channels
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and are persistent chemicals that accumulate in fatty tissue in
the food chain.
In a nested case-control study maternal serum levels
of p,p󸀠-DDE during pregnancy and T1DM development in
the child, there was no significant association with T1DM;
however the T1DM cases had a tendency of lower p,p󸀠-DDE
levels than control subjects (as mentioned above for PCB)
[17].
Serum levels of DDT and DDE are both associated with
the development of T2DM [33, 43, 45–47]. It has been shown
that DTT activates AhR-signaling and can induce apoptosis
in murine embryonic neuronal cells, but there are no reports
available about beta-cell toxicity [146].
3.4. Polybrominated Diphenyl Ethers (PDBE). PDBEs are bio-
accumulating persistent chemicals used as flame retardants
in building materials, textiles, furnishings, and electronics.
Exposure to humans is mainly via ingestion of food and by
inhalation of indoor air and they can act as an endocrine
disruptors.
There are no epidemiological studies investigating asso-
ciations between PDBE exposure and T1DM in humans. In a
rat exposure study 2,2󸀠,3,3󸀠,4,4󸀠,5,5󸀠,6,6󸀠-decabromodiphenyl
ether (BDE209) exposure was shown to induce hyper-
glycemia, decrease insulin, glutathione, and superoxide dis-
mutase serum levels and increase TNF𝛼 serum levels, proba-
bly via induction of oxidative damage and was further corre-
lated to changes in rat liver cell MHC and TNF𝛼 transcripts
that possibly could be involved in T1DM development [49].
In a study on porcine alveolar cells, a mix of PDBE, DE-
71 was shown to induce lower levels of proinflammatory
cytokine release compared to control, indicating that PDBEs
may suppress innate immunity [50].
PDBEs have been suggested to be associated with altered
thyroxin hormone levels, and there are conflicting reports on
association with T2DM in humans [47, 48, 51, 52].
3.5. Perfluorinated Alkyl Substances (PFAS). PFAS have at-
tractive lipid and water repelling properties and are therefore
used in fire-fighting foam, textiles, kitchen ware, and food
packaging materials. Human exposure to PFAS is mainly
through diet via marine food and game.
An epidemiological study has reported that increased
serum level of the perfluorononanoic acid (PFNA) in human
adolescents is associated with decreased blood insulin and
beta-cell function [54].
PFAS exposure in utero appears to modulate the immune
response in children, resulting in reduced immune responses
to vaccines and increased infections in early childhood
[55, 57]. In a human cumulative health risk assessment
report PFAS are suggested to be immunotoxic, although
the mechanisms are unknown and possible multiple [58].
Further, elevated PFNA serum level was also associated with
diabetes in an elderly population supporting the view that
PFAS can alter glucose metabolism in humans and induce
T2DM [53]. Lv et al. [56] reported that PFAS exposure in
rats during gestation and lactation altered glucose tolerance
in adult offspring.
3.6. Bisphenol A (BPA). BPA is used in the production of
polycarbonate plastic and epoxy resins coating the inside of
metal cans and can leak from the plastic into food. Human
exposure is ubiquitous, as BPA metabolites are measured
in more than 90% of children and adults in westernized
countries [147]. BPA is rapidly metabolized and more than
99% is secreted in the urine within 4 hours [148], making
detection in human blood samples variable and inconsistent
at the limit of detection.
No human study of BPA exposure and T1DM develop-
ment has been performed. Using the NOD mouse model,
BPA was found to increase the spontaneous T1DM develop-
ment after both long term postnatal exposure and short term
prenatal and early life exposure [59, 60]. A very high BPA
exposure (resembling 15mg/kg/day) showed tendency to a
preventive effect, which possibly could be explained by dif-
ferent mechanisms dominating at higher BPA exposure, such
as an increased insulin secretion or estrogenic compensation
mechanisms. These studies suggest that BPA acts by impair-
ing macrophage function, resulting in impaired clearance of
apoptotic cells, a feature common for several autoimmune
diseases. BPA was also seen to modulate immune responses
in lymphoid tissue in themice and to impair isletmorphology
and beta-cell function in isolated rat pancreatic islets [60, 62].
Epidemiological studies have shown both positive and no
associations to T2DM [61, 63, 65, 67–69]. In addition, BPA
exposure has also been associated with asthma development
in both human epidemiological studies and animal experi-
mental studies [149–152]. It has been shown that BPA induces
insulin secretion, in both human and mouse beta-cells via
ER𝛽 activation, possibly contributing to T2DM development
[64, 66]. Further animal studies have shown induced insulin
resistance and T2DM in mice [66, 145, 153–157].
3.7. Triclosan. Triclosan is a chlorinated aromatic compound
that has anti-inflammatory effects, suppressing microbial-
pathogen recognition pathway molecules and chronic medi-
ators of inflammation and is used as antimicrobial agent in
soap, toothpaste, clothes, and suture material for medical
surgery [158].
There are no epidemiological studies investigating associ-
ations between triclosan exposure andT1DMor T2DM; how-
ever, triclosan exposure has been associated with increased
risk of sensitization, rhinitis, and food allergy [159–161].
As an endocrine disruptor, triclosan has been shown to
decrease thyroid hormone levels in humans and in rats [71–
73]. Treatment with tri-iodothyronine (T3) in the BB rat
reduced T1DM incidence and increased beta-cell mass in
diabetes free Wistar rats [162], indicating that modulation
of thyroid hormone levels may affect T1DM development in
genetically susceptible animals.
3.8. Phthalates. Phthalates are commonly used as plasticizers
and in a variety of consumer products, like paint and
cosmetics. Phthalates are rapidly biodegradable endocrine
disruptors and human exposure is mainly through diet via
contamination from plastic into food and via inhalation of
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phthalates in dust in indoor air. Uptake via the skin from
cosmetic products is also contributing to systemic exposure.
No epidemiological studies have so far investigated asso-
ciations between phthalate exposure and T1DM. There are,
however, epidemiological studies showing associations with
phthalate exposure and insulin resistance and T2DM [62,
74, 76, 78, 80–83]. Phthalates can induce sustained oxidative
stress and inflammation via activation of AhR, ER, and/or
binding to peroxisome proliferator activated receptor PPARs
[75, 77, 79, 163, 164]. Phthalate exposure is also associated
with asthma development and Th2 deviation, possibly via
epigenetic modulations [164–167].
3.9. Arsenic. Arsenic is often contaminating drinking water
from private wells, in high levels especially throughout South
East-Asia and Latin-America but also in lower levels in parts
of the United States, Australia, and Europe [86, 168].
There are no epidemiological studies investigating asso-
ciations between arsenic exposure and T1DM development.
Arsenic exposure has been shown to impair the immune
system in humans and animal models [86, 89, 91] and to alter
the gut microbiome diversity, microbiome metabolic profiles
as well as inhibiting the glucose stimulated insulin release in
mice [85, 93]. Further, prenatal arsenic exposure has been
associated with increased miRNAs (miR-107 and miR-126)
involved in signaling pathways related to diabetes [84, 169]
and another possible mechanism for diabetes development
can be a direct negative effect on beta-cell functions and
apoptosis due to arsenic exposure seen in MIN6 pancreatic
murine and RIN-m5F rat beta-cell lines [44, 88].
Epidemiological studies have reported an association
between arsenic exposure and T2DM [87, 90, 92, 94, 170].
3.10. Organotin Compounds. Organotin compounds are used
as stabilizers in the production of polyvinyl chloride, and
triphenyltin compounds are used as antifungal agents [171].
There are no present epidemiological study investigating
associations between organotin compounds and diabetes in
humans. However, triphenyltin exposure has been shown to
cause hyperglycemia in rabbits and hamsters, possibly due
to inhibitory effects on insulin secretion by decreasing the
glucose-induced rise in intracellular Ca2+ in pancreatic beta-
cells, as shown in triphenyltin exposed hamsters [95, 96].
Triphenyltin exposure did not affect diabetes development in
rats and mice [98], although it has recently been shown that
tributyltin chloride induces pancreatic islet cell apoptosis in
male KMmice [97].
3.11. N-Nitroso Compounds. N-nitroso compounds are
present in processed food [172] but can also be formed in
the gastrointestinal tract when nitrates from food or water
are converted to nitrites and reacts with amines. These
compounds are shown to be toxic to pancreatic beta-cells
[102].
Higher levels of nitrates in drinking water have been
associated with increased incidence of T1DM [105–107],
although case-control studies on children’s dietary intake of
nitrates show conflicting results [99–101, 103, 104, 173–178].
Nitrosamines in food additives have been associated with a
higher risk for T1DM development [99–101].
An exposure study with smoked/cured mutton contain-
ing N-nitroso compounds, fed at the time of mating, during
gestation and in early life in the normal nondiabetic mouse
strain CD1 showed development of diabetes in the offspring,
more pronounced in male offspring compared to females
(16% compared to 4%) [100].
3.12. Vacor. N-nitroso-compounds have previously been
used as pest control chemicals and the rodenticide Vacor is
shown to specifically decrease beta-cell functions by inhibit-
ing mitochondrial ATP production and suppressed glucose-
induced insulin secretion in isolated rat pancreatic islets and
beta-cells [116, 118–120].
3.13. Streptozotocin. Streptozotocin is a naturally occurring
glucosamine-nitrosourea compound produced by the soil
microbe Streptomyces achromogenes causing destruction of
beta-cells via DNA fragmentation, activating poly ADP-
ribosylation, formation of superoxide radicals, hydrogen
peroxide, and liberation of nitric oxide [11, 108, 113]. It is
exclusively taken up by beta-cells via the glucose transport
proteinGLUT2due to its similarity to glucose and the toxicity
is therefore specific to beta-cells [109, 111]. Multiple low dose
exposure of streptozotocin is used in animal studies to induce
beta-cell destruction associated with pancreatic insulitis and
subsequent T1DM-like symptoms [108, 110, 112]. Another
toxic glucose analogue used in rodents to induce diabetes
is alloxan, an oxygenated pyrimidine derivative. Alloxan
generates reactive oxygen species (ROS), superoxide radicals,
hydrogen peroxide, and, in a final iron-catalysed reaction
step, hydroxyl radicals that together with increased cytosolic
calcium concentration induce beta-cell death [11, 108, 114].
3.14. Bafilomycin. Bafilomycin from Streptomyces-infected
vegetables has been shown to specifically decrease beta-cell
function, seen as reduction of islet size and beta-cell mass
after injection in mice [116, 179]. Bafilomycin exposure in
utero, but not after birth, significantly accelerated the onset
and incidence of diabetes in NOD mice [115], indicating that
naturally occurring environmental toxicants possibly could
influence T1DM risk. However, such association has not been
investigated in epidemiological T1DM studies. Furthermore,
high dose bafilomycin exposure was shown to promote cell
death whereas low dose induced insulin secretion in the
MIN6 mouse pancreatic cell line [117].
3.15. Cereulide. Cereulide is a toxin produced by certain
strains of Bacillus cereus, a bacterium connected to emetic
food poisonings from raw milk and industrially produced
baby food [180].
There are no epidemiological studies investigating asso-
ciations between cereulide exposure in human and diabetes
development.
Cereulide has, however, been shown to cause necrotic
cell death in porcine pancreatic Langerhans islets in cell
culture [121] and to inducemitochondrial stress markers (p53
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upregulated modulator of apoptosis, Puma, and CCAAT/-
enhancer-binding protein homologous protein, CHOP) and
apoptosis in mouse (MIN6) and rat (INS-1E) beta-cell lines,
as well as in mouse islets [122].
3.16. Air Pollution. Cumulative exposure to ozone and sul-
phate in ambient air in Southern California has been
associated with T1DM development [129]. Animal ozone
exposure experiments, however, revealed induced glucose
intolerance in rats [130]. Further, carbon monoxide (CO) has
been associated with T2DM [131, 132]. Interestingly, carbon
monoxide has been used as treatment of T1DM in the NOD
mouse model due to its anti-inflammatory and antiapoptotic
properties [133].
Exposure to particulate matter (PM) induces formation
of reactive oxygen species in human lung endothelial cells
and circulating monocytes, leading to DNA damage and
inflammation [124, 126].
Fine particulate matter (PM2.5) has been associated with
diabetes in rats, by intratracheal instillation, enhanced insulin
resistance, and visceral inflammation in rats fed a high fat diet
but not a normal chow [70, 128]. In humans, air pollution
measured as outdoor PM < 10 𝜇m in aerodynamic diameter
(PM10) and nitrogen dioxide (NO2) has been shown to
be associated with T2DM [123, 125] and decreased insulin
sensitivity [127].
3.17. Tobacco Smoke. Maternal smoking during pregnancy
has been associated with decreased T1DM development [135,
136, 138–142], although passive smoking was more frequent
in children with T1DM in one study [129].
An association between prenatal and postnatal tobacco
smoke and increased insulin resistance has been shown in 10
year old children [134]. Further studies have shown increased
risk of T2DM due to maternal smoking, as well as increased
insulin resistance and increased risk of T2DM development
due to direct smoking in adults [137].
3.18. Polycyclic Aromatic Hydrocarbons (PAHs). PAHs are
found in fossil fuels and tar deposits and are produced
during incomplete combustion of organic matter and thus
are abundant in air pollution. In addition, considerable PAH
exposure is experienced from dietary sources [181].
We are not aware of any studies on PAH and risk of T1DM
in humans. Animal and human in vitro cell studies link PAH
exposure to the generation of oxidative stress, DNA damage
and inflammation via activation of the aryl hydrocarbon
receptor (AhR) in the metabolism and secretion of the PAHs
by CYP enzymes [23, 124, 126, 182].
The impaired regulatory T cell (Treg) function associ-
ated with human PAH and ambient air pollution exposure,
explained by increased methylation of the transcription
factor Foxp3 in Tregs [144], may be a plausible mechanism
for promoting T1DM development, although this has not yet
been investigated. Epidemiological studies have shown asso-
ciation between urinary PAH levels and T2DM development
[143].
4. Mechanisms for Chemical-Induced
Triggering of T1DM
4.1. Toxic Effects on Beta-Cells. Direct effects on beta-cell
function or viability could be a mechanism of environmental
chemical for contributing to autoimmunity. Suggested mech-
anisms leading to beta-cell apoptosis are related to altered
mitochondrial functions and induction of oxidative stress.
Other mechanisms than apoptosis leading to reduced beta
cell mass include impairment of beta-cell replication, by
cAMP suppression via 𝛼
2
-adrenergic receptors and thereby
reducing total beta-cell mass [183]. It has also been shown
that adenosine receptor agonists acting through the adeno-
sine receptor A2aa, increased beta-cell proliferation and
accelerated restoration of normoglycemia in zebrafish [184].
Regarding ATP purinoceptors, increased beta-cell apoptosis
has been reported in P2X(7) knock-out mice [185]. Glucose
is shown to induce ATP release in a mouse beta-cell line
and ADP activation of P2Y(13) receptors to inhibit insulin
release [186]. In rodent aswell as human pancreatic beta-cells,
extracellular ATP has been proposed as a paracrine signal
amplifying glucose-induced insulin secretion via P2X(3)
receptor activation [187]. Further, it has been reported that
ATP activation of P2X(7) receptors in peritoneal mouse
macrophages mediated free fatty acid release, substrate
for many enzymes including cyclooxygenases that promote
inflammation [188]. Environmental chemicals could possibly
induce extracellular accumulation of ATP followingTh2-type
inflammatory responses, similar to what has been shown for
airborne fungal allergens in na¨ıve mice [189]. Activation of
estrogen receptors ER𝛼 can cause enhancement of glucose-
induced insulin biosynthesis, reduction in islet toxic lipid
accumulation and promote beta-cell survival from pro-
apoptotic stimuli, and activation of ER𝛽 can increase glucose
induced insulin secretion in both rodent and human beta-
cells [190]. Activation of AhR can induce oxidative stress,
DNA damage and inflammation [23]. Chemicals influencing
the gap junctions between beta-cells could increase toxicity
and susceptibility to cytokine induced apoptosis, as shown
when downregulating connexin36 in INS1E-cells, suggested
to be involved in Ca2+ homeostasis within the endoplasmatic
reticulum ER [191].
BPA, PFAS, TCDD, streptomycin, alloxan, N-nitro-so
compounds, streptozotocin, zinc, organotins, and bafilo-
mycin are all shown to cause alterations in beta-cell function
and structure and/or apoptosis in animal studies [44, 54, 59,
60, 62, 88, 102].
4.2. Immunomodulation. In addition to direct effects on
beta-cell numbers and function and glucose-insulin balance,
environmental chemicals may affect T1DM development by
modulating the function of innate and adaptive immune
cells. Recurring infections in early childhood could trigger
the immune system and possibly boost autoimmunity, and
enteroviral infections in early life are associated with T1DM
development [192, 193]. As an example PFAS exposure in
utero appears to modulate the immune response in chil-
dren, resulting in reduced vaccine responses and increased
infections in early childhood [55, 57]. The increased risk of
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infections may indirectly give increased risk of enteroviral
infections triggering T1DM development in children with
auto antibody positivity.Other chemicals, such as for instance
PAHs, are reported to reduce the numbers and function of
regulatory T-cells [144, 194], cells that are important in the
suppression of the autoreactive T-cells that are key players in
the induction of autoimmunity. Corsini et al. [195] showed
that several PFAS decrease LPS-induced cytokine secretion
in human peripheral blood leucocytes and Brieger et al.
[196] showed a direct increased cytotoxicity to human NK
cells by PFAS (PFOA) exposure. Altered cytokine secretion,
reduced regulatory T-cells or Th17 cells by environmental
chemicals could be plausible explanations for a modified
immune response and the development of autoimmunity. It
has been shown that exposure not only to PFAS, but also to
BPA, phthalates, arsenic, PCB, and air pollution can alter the
cytokine balance in human and mice cells in vitro and a shift
in cytokine balance is further associated with development of
autoimmunity [59, 60, 195, 197–202].
Another suggested immunological process linking viral
infections to T1DM onset is molecular mimicry [203]. There
is a high degree of homology between human Glutamic Acid
DecarboxylaseGAD65, a pancreatic enzyme considered to be
an important autoantigen involved in T1DM development,
and a heat shock protein from the Mycobacterium avium
subspecies paratuberculosis, MAP Hsp65, and it has been
shown that T1DM patients can have antibodies against MAP
Hsp65 [204]. It has been suggested that there is a cross-
reactivity between MAP Hsp65 and GAD65, implying that
biological mimicry potentially could be a mechanism of
triggering TIDM. It has also been reported that antibodies
from T1DM patients recognizing MAP3865c epitopes from
the Mycobacterium avium could cross-react with ZnT8,
another autoantigen in T1DM development [205], although
this hypothesis has not been verified in epidemiological
studies. Other environmental factors, including chemicals,
can in principal change exogenous and endogenous proteins,
leading to mimicry pathways of T1DM triggering.
Improper activation of the immune system may lead to
allergy development or trigger autoimmunity, and exposure
to PFAS, arsenic, BPA, phthalates, air pollution, ozone, nitric
oxide, particulate matter, triclosan, PAHs, tobacco smoke,
dioxin, and PCBs have all been reported to be associated
with asthma and/or allergy in several epidemiological studies
[42, 149, 150, 165, 206–215].
BPA and PDBEs have been shown to reduce cytokine
secretion from macrophages, and BPA and arsenic seem to
impair phagocytic activity in macrophages, possibly leading
to a reduced clearance of apoptotic cells in pancreatic islets
which can result in an induced insulitis in the NOD mouse
[50, 91, 216].
4.3. Epigenetics. Epigenetic alterations, via histone modi-
fications, DNA methylation and microRNA dysregulation
leading to altered gene expression, represent one way in
which chemicals can induce effects early in life that manifest
disease later in life. Emerging data suggest that prenatal
exposures, like for instance to arsenic, may induce epigenetic
alterations, already measurable in umbilical cord blood [84,
217]. Prenatal exposure to phthalates and postnatal exposure
to BPA have been suggested to work together in a “two-hit
model” on hormonal alterations leading to epigenetic regu-
lation of gene expression [149]. Phthalate exposure has been
shown to induce DNA methylation of the estrogen receptor
alpha in a breast cancer cell line [218]. Environmental factors
such as pharmaceuticals, pesticides, air pollutants, industrial
chemicals, heavy metals, hormones, nutrition, as well as
behavior have been suggested to change gene expression with
demonstrated changes in epigenetic markers [214, 218, 219].
Alterations in micro-RNA levels might influence beta-cell
functions and overexpression of microRNAmiR375 has been
shown to be associated with suppressed glucose induced
insulin secretion by reduced levels of PDK1 leading to
reducing beta-cell viability and cell number [220]. IL-1𝛼 and
TNF𝛼 induce miR21, miR34a, and miR146a in human and
NOD mouse pancreatic islets and in the mouse MIN6 beta-
cell line and are involved in cytokine-induced cell death [221].
The miR21 as well as miR34a reduces beta-cell apoptosis
and protects against T1DM development [222, 223], while
overexpression of miR29a/b/c was reported to promote beta-
cell apoptosis [224].
4.4. Microbiota. The microbiota composition in the gut has
been shown to be crucial for developing a healthy immune
system in animals. The right composition is suggested to
support oral tolerance and protect against enteral virus
infections, and microbial colonization of Bifidobacterium has
been shown to be lower in patients with T1DM [6, 225–230].
Transfer of microbiota from Myd88-/-NOD mice, which are
protected from diabetes, has been shown to reduce insulitis
and delay T1DM development in the normal diabetes prone
NOD recipient [231]. Furthermore, alterations in microbiota
composition results in altered hormone levels in the NOD
mouse [232]. Nutritional and chemical constituents in our
diet and drinking water have been shown to alter the micro-
biota composition in animals [233–235] and future studies
are needed to clarify the importance of such interactions
between environment, microbial flora and autoimmunity.
On the other hand, probiotics could possibly interfere with
T1DM development and examples hereof are animal studies
with probiotics given to the T1DM prone NOD mouse
showing protective effects against T1DM development via
Th17 induction [236–239]. In an epidemiological context,
the ongoing PRODIA study will elucidate if introduction to
probiotics during the first 6 months of life decreases the
appearance of T1DM-associated autoantibodies in children
with genetic risk for T1DM [240].
4.5. Intestinal Permeability. Increased intestinal permeability
is an early feature of diabetes before the onset of the disease
in the Bio Breeding T1DM rat model, and blocking of the
tight junction modulator zonulin has been shown to inhibit
the disease in this model [241, 242]. Increased intestinal
permeability has also been shown to be an early event in
T1DMpatientswith upregulation of zonulin prior to the onset
of the disease [229, 243–247].
Chemicals, like heavy metals and organochloride pesti-
cides, can possibly affect intestinal permeability, as well as
BioMed Research International 11
impairing the osmoregulation and calcium transport [248,
249]. Lactobacillus has been shown to reduce the intestinal
permeability via relocation of occludin and ZO-1 into the
tight junction area between duodenal epithelial cells after
short term administration to healthy volunteers [250] and
this mechanism together with alterations in hormone levels
could possibly explain a beneficial effect of probiotics in the
NODmouse model [236–239].
5. Summary
We have presented literature supporting a possible role of
environmental chemicals to act as triggers or accelerators
for T1DM development. Chemicals may have direct toxic
effects on insulin producing beta-cells or have immunemod-
ulatory effects, alter hormone levels, affect the microbiota,
or alter intestinal permeability. Chemical-induced epigenetic
alterations leading to altered gene expression are probably
involved, in particular in relation to in utero effects.
Whether the doses of environmental chemicals to which
humans are exposed are sufficient to impact the risk of T1DM
remains largely unexplored.Due to lack of strong evidence for
a single factor as the major trigger for T1DM development it
is tempting to propose that several factors have additive or
synergistic effects, acting via several mechanisms and/or at
different stages in the disease development. Human exposure
to environmental chemicals is complex. While some chemi-
cals may have beneficial effects, others may have detrimental
effects in individuals with autoimmune predisposition, and
the adverse consequences of this sum of exposures can-
not be elucidated with the information available. Further
observational T1DM cohort studies with determination of
several biomarkers of chemical exposure in serum and urine,
together with animal and cellular experiments using single
and combined chemical exposures are encouraged.
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